Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: A new clinical scenario for castration-resistant prostate cancer?

Clinical Genitourinary Cancer

Volumn 11, Issue 4, 2013, Pages

  Caffo, Orazio ^a   Palermo, Antonio ^a   Veccia, Antonello ^a   Maines, Francesca ^a   Chierichetti, Franca ^a   Galligioni, Enzo ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

Author keywords

Abiraterone; Castration resistant prostate cancer; Choline positron emission tomography; Withdrawal response

Indexed keywords

ABIRATERONE ACETATE; DOCETAXEL; GONADORELIN AGONIST; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; HUMAN; MALE; METABOLIC REGULATION; METASTASIS; MULTIPLE CYCLE TREATMENT; PROSTATE ADENOCARCINOMA; WITHDRAWAL SYNDROME;

ABIRATERONE; CASTRATION RESISTANT PROSTATE CANCER; CHOLINE POSITRON EMISSION TOMOGRAPHY; WITHDRAWAL RESPONSE;

AGED; ANDROSTADIENES; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; STEROID 17-ALPHA-HYDROXYLASE; SUBSTANCE WITHDRAWAL SYNDROME; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT FAILURE;

EID: 84888014912     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.04.021     Document Type: Article

References (17)

1. R. Paul, and J. Breul Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance Drug Saf 23 2000 381 390
2. E.J. Small, S. Halabi, and N.A. Dawson Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) J Clin Oncol 22 2004 1025 1033
3. A.O. Sartor, C.M. Tangen, and M.H. Hussain Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426) Cancer 112 2008 2393 2400
4. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
5. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
6. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
7. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
8. H. Gauthier, G. Bousquet, and D. Pouessel Abiraterone acetate withdrawal syndrome: does it exist? Case Rep Oncol 5 2012 385 387
9. L. Albiges, E. Auclin, and B. Rousseau Is there a withdrawal syndrome with abiraterone acetate (AA)? (abstract 89) J Clin Oncol 2013 31
10. G. Han, G. Buchanan, and M. Ittmann Mutation of the androgen receptor causes oncogenic transformation of the prostate Proc Natl Acad Sci U S A 102 2005 1151 1156
11. G. Wilding, M. Chen, and E.P. Gelmann Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens Prostate 14 1989 103 115
12. J. Veldscholte, C. Ris-Stalpers, and G.G. Kuiper A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens Biochem Biophys Res Commun 173 1990 534 540
13. M. Jarman, S.E. Barrie, and J.M. Llera The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors J Med Chem 41 1998 5375 5381
14. C. Cai, S. Chen, and P. Ng Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors Cancer Res 71 2011 6503 6513
15. E.A. Mostaghel, B.T. Marck, and S.R. Plymate Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants Clin Cancer Res 17 2011 5913 5925
16. E. Efstathiou, M. Titus, and D. Tsavachidou Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone J Clin Oncol 30 2012 637 643
17. X.Y. Zhao, P.J. Malloy, and A.V. Krishnan Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat Med 6 2000 703 706